Halozyme Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
Hello, everyone. Welcome to the afternoon session of Day 3 of the Bank of America Virtual Vegas Healthcare Conference. I'm Greg Harrison, U.S. biopharma analyst here at BofA, and I'm very excited that we have Halozyme with us here today. And here to speak on behalf of Halozyme is CEO, Helen Torley. The format is going to be a fireside chat. So feel free to send in questions, and I can ask them anonymously.
Questions & Answers
So Helen, let's just move right on to the Q&A. And maybe you could give the listeners, who maybe aren't as familiar, just an overview of as what is the ENHANZE technology? And how does the business model around that work?
Yes. Thanks, Greg. I appreciate being here. So ENHANZE is Halozyme's proprietary enzyme, which is called rHuPH20. It is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
